Clinical Trials Browser

Terminated × Mesothelioma, Malignant × osimertinib × Clear all

NCT05228015 2024-11-18

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasmThoracic

Mesothelioma, Malignant, Hemangioendothelioma, Epithelioid